Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
U351248-5mg | 5mg | In stock | $98.90 | |
U351248-10mg | 10mg | In stock | $167.90 | |
U351248-25mg | 25mg | In stock | $378.90 | |
U351248-50mg | 50mg | In stock | $503.90 | |
U351248-100mg | 100mg | In stock | $907.90 | |
U351248-200mg | 200mg | In stock | $1,632.90 |
Synonyms | URB937|1357160-72-5|3'-carbamoyl-6-hydroxybiphenyl-3-yl cyclohexylcarbamate|URB 937|URB-937|CHEMBL2402927|[3-(3-carbamoylphenyl)-4-hydroxyphenyl] N-cyclohexylcarbamate|3'-Carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl cyclohexylcarbamate|SCHEMBL528582|GTPL11817 |
---|---|
Specifications & Purity | 98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of Fatty acid amide hydrolase |
Product Description | Product description URB937 is an orally active and peripherally restricted FAAH inhibitor (IC50=26.8 nM) and increases anandamide levels. URB937 fails to affect FAAH activity in the brain (not penetrate the blood-brain barrier). |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | [3-(3-carbamoylphenyl)-4-hydroxyphenyl] N-cyclohexylcarbamate |
---|---|
INCHI | InChI=1S/C20H22N2O4/c21-19(24)14-6-4-5-13(11-14)17-12-16(9-10-18(17)23)26-20(25)22-15-7-2-1-3-8-15/h4-6,9-12,15,23H,1-3,7-8H2,(H2,21,24)(H,22,25) |
InChi Key | CMEQHOXCIGFZNJ-UHFFFAOYSA-N |
Canonical SMILES | C1CCC(CC1)NC(=O)OC2=CC(=C(C=C2)O)C3=CC(=CC=C3)C(=O)N |
Isomeric SMILES | C1CCC(CC1)NC(=O)OC2=CC(=C(C=C2)O)C3=CC(=CC=C3)C(=O)N |
WGK Germany | 3 |
PubChem CID | 53394762 |
Molecular Weight | 354.4 |
PubChem CID | 53394762 |
---|---|
CAS Registry No. | 1357160-72-5 |
ChEMBL Ligand | CHEMBL2402927 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
C23081457 | Certificate of Analysis | Dec 01, 2022 | U351248 |
C23081470 | Certificate of Analysis | Dec 01, 2022 | U351248 |
C23081471 | Certificate of Analysis | Dec 01, 2022 | U351248 |
C23081472 | Certificate of Analysis | Dec 01, 2022 | U351248 |
C23081477 | Certificate of Analysis | Dec 01, 2022 | U351248 |
C23081480 | Certificate of Analysis | Dec 01, 2022 | U351248 |
WGK Germany | 3 |
---|---|
RIDADR | NONHforallmodesoftransport |
1. Slivicki RA, Xu Z, Mali SS, Hohmann AG. (2019) Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.. Pharmacol Res, 142 (3): (267-282). [PMID:30739035] |